Show simple item record

dc.contributor.authorMutimer, David
dc.contributor.authorElsharkawy, Ahmed
dc.contributor.authorHathorn, Emma
dc.contributor.authorArunkumar, Selvi
dc.date.accessioned2023-07-25T11:58:22Z
dc.date.available2023-07-25T11:58:22Z
dc.date.issued2023-06-01
dc.identifier.citationMutimer D, Elsharkawy A, Hathorn E, Arunkumar S. Rate and determinants of antiviral treatment initiation for patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2023 Aug;30(8):694-699. doi: 10.1111/jvh.13841. Epub 2023 Jun 1. PMID: 37260033.en_US
dc.identifier.eissn1365-2893
dc.identifier.doi10.1111/jvh.13841
dc.identifier.pmid37260033
dc.identifier.urihttp://hdl.handle.net/20.500.14200/1334
dc.description.abstractMost clinic attenders with chronic hepatitis B (CHB) are serum HBeAg-negative, and a minority will require suppressive antiviral treatment. Expert guidelines propose schedules for the monitoring of untreated patients, but the recommended frequency of patient review does not reflect recognised demographic determinants of HBeAg-negative chronic hepatitis. Also, the impact of patient ethnicity on risk has not been defined. The aim of our study was to determine the rates and determinants of antiviral treatment initiation in a large multi-ethnic cohort of CHB patients attending a single centre. We undertook a retrospective study using entirely electronic sources of patient information. Treatment initiation dates were identified from electronic pharmacy records. Crude and time-dependent statistical analyses were undertaken to identify rate and risk factors for treatment initiation. Treatment was initiated for 232/1256 (18.5%) patients with rates of 23.2% and 33.2% at 5 and 10 years. An increased risk of treatment was associated with male sex (RR 1.803), older age at presentation (RR 1.027 per year increase) and with non-Black ethnicity (RR 1.654). Patient sex, baseline age and ethnicity also determined risk for treatment in the subset of patients with normal serum ALT and low HBV DNA at baseline, though overall treatment rate in this group was low (only 2% per annum). Thus, patient demographics permit risk stratification for treatment initiation and could determine to a significant extent the frequency of review required for untreated HBeAg-negative patients. Black ethnicity is associated with a significant reduction in risk of treatment initiation.en_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/jvh.13841en_US
dc.rights© 2023 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.
dc.subjectGastroenterologyen_US
dc.titleRate and determinants of antiviral treatment initiation for patients with HBeAg-negative chronic hepatitis B.en_US
dc.typeArticle
dc.source.journaltitleJournal of Viral Hepatitis
dc.source.volume30
dc.source.issue8
dc.source.beginpage694
dc.source.endpage699
dc.source.countryEngland
rioxxterms.versionNAen_US
dc.contributor.trustauthorMutimer, David
dc.contributor.trustauthorArunkumar, Selvi
dc.contributor.departmentGastroenterologyen_US
dc.contributor.departmentHealth Informaticsen_US
dc.contributor.roleAdditional Professional Scientific and Technical Fielden_US
dc.contributor.roleMedical and Dentalen_US
oa.grant.openaccessnaen_US


This item appears in the following Collection(s)

Show simple item record